SPRR2A and neoplasm: Interestingly, all four mice previously treated with MeVac H IgG1-Fc, six out of ten mice previously treated with MeVac P FmIL-12, and five of six mice from the MeVac ld FmIL-15 group rejected secondary tumor engraftment, indicating a systemic, protective antitumor immune response following treatment with oncolytic measles vectors.